Table 2 Foundation ONE reports of CBL alterations with EGFR, MET, or KRAS alterations and patient treatment outcome.

From: Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL

Patient	Tumor type	CBL mutation	EGFR/MET/KRAS mutation	Chemo/Clinical Trial	Outcome
1	Lung AD	H37_H38insHH	*EGFR* E746_A750del, T790M	Erlotinib	Was effective for a time but progressive disease
				AP26113	1. Interval progression of disease with interval increase in the size of the left lung mass, hepatic metastases, also as metastases and left adrenal metastatic disease.
				AP26113	2. Interval development of right-sided pulmonary static disease.
2	Lung AD	A848T	*EGFR* E746_A750del, amplification	Carboplatin	Unknown. Tolerated Well
				Paclitaxel	Unknown. Tolerated Well
				Erlotinib	Good response but discontinued due to poor performance status
3	Lung AD	T810S, amplification	*EGFR* R429S	Carboplatin	1. No new suspicious pulmonary nodules or masses.
				Carboplatin	2. Stable upper mediastinal right paratracheal soft tissue mass at the site of prior resection.
				Paclitaxel	1. No new suspicious pulmonary nodules or masses.
				Paclitaxel	2. Stable upper mediastinal right paratracheal soft tissue mass at the site of prior resection.
4	NSCLC (NOS)	S80G		Carboplatin	Unknown
4	NSCLC (NOS)	S80G		Gemcitabine	Unknown
5	Lung AD	A848T, E886K	*EGFR* R1068, P518L; KRAS* G10R, K169N	Carboplatin	1. No significant interval change in the large necrotic right anterior mediastinal mass with extension into the right hilum and right chest wall and sternal/pericardial/SVC invasion.
					2. Mild interval improvement in number of pulmonary nodules, specifically in the right upper lobe.
					3. Stable retroperitoneal lymphadenopathy.
					4. Nonspecific sclerotic focus in vertebral body of T3.
				Paclitaxel	1. No significant interval change in the large necrotic right anterior mediastinal mass with extension into the right hilum and right chest wall and sternal/pericardial/SVC invasion.
					2. Mild interval improvement in number of pulmonary nodules, specifically in the right upper lobe.
					3. Stable retroperitoneal lymphadenopathy. 4. Nonspecific sclerotic focus in vertebral body of T3.
6	Lung AD	E366*		CALGB 30303, Phase II IRB 13724 A trial of Docetaxel and Cisplatin	Unknown
6	Lung AD	E366*		Carboplatin	Marked improvement of disease.
7	Lung AD	R420Q	*KRAS* G12C	No Chemotherapy/Trial
8	NSCLC (NOS)	K54E		Carboplatin	1. Good response.
					2. Interval decrease in size of left upper lobe mass and left hilar/subsegmental lymph node.
					3. Left upper lobe mass is now mostly cavitary.
				Paclitaxel	1. Good response.
					2. Interval decrease in size of left upper lobe mass and left hilar/subsegmental lymph node.
					3. Left upper lobe mass is now mostly cavitary.
9	NSCLC (NOS)	A757T	*KRAS* amplification, G12V	Cisplatin	Clinically no evidence of disease
				Docetaxel	Clinically no evidence of disease
				Carboplatin	Response in some areas, but progression in right kidney (mixed response?)
				Gemcitabine	Response in some areas, but progression in right kidney (mixed response?)
10	Lung AD	Amplification	*EGFR* L858R	Carboplatin	1. No evidence of acute pulmonary embolus.
					2. New geographic areas of groundglass opacities in the right lung.
					3. Differential diagnosis includes drug toxicity, atypical infection, and hemorrhage.
					4. Stable left lingular mass, sclerotic osseous foci, and metastatic hepatic lesions.
				Paclitaxel	1. No evidence of acute pulmonary embolus.
					2. New geographic areas of groundglass opacities in the right lung.
					3. Differential diagnosis includes drug toxicity, atypical infection, and hemorrhage.
					4. Stable left lingular mass, sclerotic osseous foci, and metastatic hepatic lesions.
				Erlotinib	Good response but discontinued due to poor performance status

AD: adenocarcinoma; NOS: not otherwise specified.

Back to article page

Table 2 Foundation ONE reports of CBL alterations with EGFR, MET, or KRAS alterations and patient treatment outcome.

Search

Quick links